(BETA) News Briefs: Study of Enhanced Saquinavir Formulation Open to Enrollment

(BETA) News Briefs: Study of Enhanced Saquinavir Formulation Open to Enrollment

Bulletin of Experimental Treatments for AIDS, No. 26 September 1995
Ronald Baker, PhD

Researchers are actively recruiting for a Phase I/II clinical study of an enhanced, more bioavailable formulation of saquinavir (Invirase), the protease inhibitor drug from Hoffmann-La Roche.

About 90 people are needed at 10 U.S. medical centers for a dose-ranging study comparing 2 formulations of Invirase.

Participants will be randomized to 1 of 4 monotherapy treatment arms for 8 weeks. Afterwards, participants can continue on saquinavir plus the anti-HIV treatment of their choice. Trials are enrolling in Jefferson County, AL; Boston, MA; Jackson County, MO; New York, NY; Portland, OR; and Galvetson, TX. For more information about the study, call Roche at 1-800-526-6367 or 1-800-TRIALS-A.

950901
BETA2605

Always watch for outdated information. This article first appeard in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1995 - Bulletin of Experimental Treatments for AIDS (BETA). Reproduced with permission. BETA is published four times a year by the San Francisco AIDS Foundation. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. Call 415.487.8060; FAX: 415.487.8069. Mailing Address: P.O. Box 426182, San Francisco, CA 94142-6182. beta@sfaf.org http://www.sfaf.org/beta.html

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1995. AEGIS.